Skip to main content

Advertisement

SpringerLink
Log in

Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases: Making a Comeback?

  • Colorectal Cancer Hepatic Metastases (MA Choti, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Nearly half of patients diagnosed with colorectal cancer will develop metastases during their lifetime; the majority of them were found within the liver. Surgical resection of liver metastases is the only curative therapy with 5-year survival rates ranging from 40 to 58 %. Unfortunately, less than 25 % of patients are eligible for resection. Before the advent of the modern systemic chemotherapy era, the administration of hepatic artery infusion (HAI) chemotherapy was widespread in the treatment of colorectal liver metastasis (CLM). However, due to a lack of demonstrated increased survival following HAI therapy compared to systemic chemotherapy alone, its use has fallen out of favor. Recently, multiple studies have demonstrated that HAI therapy may fill a role in the treatment of CLM disease in patients who have either progressed on first-line systemic chemotherapy in the palliative setting or are considered candidates for conversion from unresectable to resectable liver-only disease. The lack of large randomized clinical trials demonstrating clinical efficacy has precluded HAI chemotherapy use to be considered standard of care outside of a research setting in the adjuvant setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Quantin C, Benzenine E, Hagi M, et al. Estimation of national colorectal-cancer incidence using claims databases. J Cancer Epidemiol. 2012;2012:298369.

    CAS  PubMed Central  PubMed  Google Scholar 

  2. Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992–2008. Cancer Epidemiol Biomark Prev. 2012;21:411–6. Cosponsored by the American Society of Preventive Oncology.

    Article  Google Scholar 

  3. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509–20. Discussion 20–2.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Finlay IG, McArdle CS. Occult hepatic metastases in colorectal carcinoma. Br J Surg. 1986;73:732–5.

    Article  CAS  PubMed  Google Scholar 

  5. Steele Jr G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg. 1989;210:127–38.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1271–80.

    Article  PubMed  Google Scholar 

  7. Donadon M, Ribero D, Morris-Stiff G, Abdalla EK, Vauthey JN. New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res. 2007;1:20–7.

    PubMed Central  PubMed  Google Scholar 

  8. Abbas S, Lam V, Hollands M. Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. ISRN Oncol. 2011;2011:763245.

    PubMed Central  PubMed  Google Scholar 

  9. Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301.

    PubMed Central  PubMed  Google Scholar 

  10. Frankel TL, D’Angelica MI. Hepatic resection for colorectal metastases. J Surg Oncol. 2014;109:2–7.

    Article  PubMed  Google Scholar 

  11. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–9.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Li W, Xu J, Shen L, et al. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. BMC Cancer. 2014;14:986.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Folprecht G, Gruenberger T, Bechstein W, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014;25:1018–25.

    Article  CAS  PubMed  Google Scholar 

  14. Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103:21–30.

    Article  PubMed  Google Scholar 

  15. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.

    Article  PubMed  Google Scholar 

  16. Ensminger WD, Rosowsky A, Raso V, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res. 1978;38:3784–92.

    CAS  PubMed  Google Scholar 

  17. Ackerman NB. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery. 1974;75:589–96.

    CAS  PubMed  Google Scholar 

  18. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969–77.

    CAS  PubMed Central  PubMed  Google Scholar 

  19. Bierman HR, Byron Jr RL, Kelley KH, Grady A. Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo. J Natl Cancer Inst. 1951;12:107–31.

    CAS  PubMed  Google Scholar 

  20. Daly JM, Kemeny N, Sigurdson E, Oderman P, Thom A. Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein. Arch Surg. 1987;122:1273–7.

    Article  CAS  PubMed  Google Scholar 

  21. Ridge JA, Bading JR, Gelbard AS, Benua RS, Daly JM. Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein. Cancer. 1987;59:1547–53.

    Article  CAS  PubMed  Google Scholar 

  22. Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol. 1987;5:1836–40.

    CAS  PubMed  Google Scholar 

  23. Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983;10:176–82.

    CAS  PubMed  Google Scholar 

  24. Callahan MK, Kemeny NE. Implanted hepatic arterial infusion pumps. Cancer J. 2010;16:142–9.

    Article  PubMed  Google Scholar 

  25. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol. 2002;29:119–25.

    Article  CAS  PubMed  Google Scholar 

  26. Wickremesekera JK, Cannan RJ, Stubbs RS. Hepatic artery access ports: recognizing and avoiding the problems. Aust N Z J Surg. 2000;70:496–502.

    Article  CAS  PubMed  Google Scholar 

  27. Campbell KA, Burns RC, Sitzmann JV, Lipsett PA, Grochow LB, Niederhuber JE. Regional chemotherapy devices: effect of experience and anatomy on complications. J Clin Oncol. 1993;11:822–6.

    CAS  PubMed  Google Scholar 

  28. Curley SA, Chase JL, Roh MS, Hohn DC. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery. 1993;114:928–35.

    CAS  PubMed  Google Scholar 

  29. Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R. Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep. 1981;65:393–400. Initial description of pharmacokinetic data for hepatic artery infusion chemotherapy agents.

    CAS  PubMed  Google Scholar 

  30. Kaplan WD, D’Orsi CJ, Ensminger WD, Smith EH, Levin DC. Intra-arterial radionuclide infusion: a new technique to assess chemotherapy perfusion patterns. Cancer Treat Rep. 1978;62:699–703.

    CAS  PubMed  Google Scholar 

  31. Dzodic R, Gomez-Abuin G, Rougier P, et al. Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anti-Cancer Drugs. 2004;15:647–50.

    Article  CAS  PubMed  Google Scholar 

  32. Kemeny N, Seiter K, Conti JA, et al. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Cancer. 1994;73:1134–42.

    Article  CAS  PubMed  Google Scholar 

  33. Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 1994;12:2288–95.

    CAS  PubMed  Google Scholar 

  34. Wagner JG, Gyves JW, Stetson PL, et al. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res. 1986;46:1499–506.

    CAS  PubMed  Google Scholar 

  35. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol. 1995;13:210–21.

    CAS  PubMed  Google Scholar 

  36. Iyer L, Ratain MJ. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol. 1998;42(Suppl):S31–43.

    Article  CAS  PubMed  Google Scholar 

  37. van Riel JM, van Groeningen CJ, de Greve J, Gruia G, Pinedo HM, Giaccone G. Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol. 2004;15:59–63.

    Article  PubMed  Google Scholar 

  38. Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23:4881–7.

    Article  CAS  PubMed  Google Scholar 

  39. Guthoff I, Lotspeich E, Fester C, et al. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res. 2003;23:5203–8.

    CAS  PubMed  Google Scholar 

  40. Cheng J, Hong D, Zhu G, Swanstrom LL, Hansen PD. Laparoscopic placement of hepatic artery infusion pumps: technical considerations and early results. Ann Surg Oncol. 2004;11:589–97.

    Article  PubMed  Google Scholar 

  41. Franklin M, Trevino J, Hernandez-Oaknin H, Fisher T, Berghoff K. Laparoscopic hepatic artery catheterization for regional chemotherapy: is this the best current option for liver metastatic disease? Surg Endosc. 2006;20:554–8.

    Article  CAS  PubMed  Google Scholar 

  42. Franklin Jr ME, Gonzalez Jr JJ. Laparoscopic placement of hepatic artery catheter for regional chemotherapy infusion: technique, benefits, and complications. Surg Laparosc Endosc Percutan Tech. 2002;12:398–407.

    Article  PubMed  Google Scholar 

  43. Daly JM, Kemeny N, Oderman P, Botet J. Long-term hepatic arterial infusion chemotherapy. Anatomic considerations, operative technique, and treatment morbidity. Arch Surg. 1984;119:936–41.

    Article  CAS  PubMed  Google Scholar 

  44. Hellan M, Pigazzi A. Robotic-assisted placement of a hepatic artery infusion catheter for regional chemotherapy. Surg Endosc. 2008;22:548–51.

    Article  PubMed  Google Scholar 

  45. Allen PJ, Stojadinovic A, Ben-Porat L, et al. The management of variant arterial anatomy during hepatic arterial infusion pump placement. Ann Surg Oncol. 2002;9:875–80.

    Article  PubMed  Google Scholar 

  46. Allen PJ, Nissan A, Picon AI, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201:57–65. Largest series detailing the complications of HAI pump insertion and its effect on survival outcome measures.

    Article  PubMed  Google Scholar 

  47. Nakanuma Y, Hoso M, Sanzen T, Sasaki M. Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply. Microsc Res Tech. 1997;38:552–70.

    Article  CAS  PubMed  Google Scholar 

  48. Ito K, Ito H, Kemeny NE, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol. 2012;19:1609–17.

    Article  PubMed  Google Scholar 

  49. Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer. 1992;69:327–34.

    Article  CAS  PubMed  Google Scholar 

  50. Kingham TP, D’Angelica M, Kemeny NE. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol. 2010;102:988–95.

    Article  PubMed  Google Scholar 

  51. Kemeny N, Capanu M, D’Angelica M, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009;20:1236–41.

    Article  CAS  PubMed  Google Scholar 

  52. Kemeny N, Gonen M, Sullivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol. 2001;19:2687–95.

    CAS  PubMed  Google Scholar 

  53. Kemeny N, Jarnagin W, Gonen M, et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol. 2003;21:3303–9.

    Article  CAS  PubMed  Google Scholar 

  54. Cercek A, D’Angelica M, Power D, et al. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. Ann Surg Oncol. 2014;21:479–86.

    Article  PubMed  Google Scholar 

  55. Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56:430–9.

    Article  PubMed  Google Scholar 

  56. Allard MA, Sebagh M, Baillie G, et al. Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases. Ann Surg Oncol. 2014;22:1925–32.

    Article  PubMed  Google Scholar 

  57. Tamandl D, Klinger M, Eipeldauer S, et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18:421–30.

    Article  PubMed  Google Scholar 

  58. Cremolini C, Loupakis F, Falcone A. FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2015;372:291–2.

    PubMed  Google Scholar 

  59. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.

    Article  CAS  PubMed  Google Scholar 

  60. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685–93.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987;107:459–65.

    Article  CAS  PubMed  Google Scholar 

  62. Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007;25:5649–54. This meta-analysis included all published randomized phase III clinical trials administering HAI chemotherapy compared to systemic chemotherapy regimens. Their conclusion was that HAI therapy offered no benefit to systemic therapy in patients with unresectable CLM.

    Article  PubMed  Google Scholar 

  63. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluoro uracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.

    Article  CAS  PubMed  Google Scholar 

  64. Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI {+/−} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25:107–16.

    Article  CAS  PubMed  Google Scholar 

  65. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706–13.

    Article  CAS  PubMed  Google Scholar 

  66. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2311–9.

    Article  CAS  PubMed  Google Scholar 

  67. Van Cutsem E, Bajetta E, Valle J, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29:2004–10.

    Article  PubMed  Google Scholar 

  68. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–506.

    Article  PubMed  Google Scholar 

  69. Karanicolas PJ, Metrakos P, Chan K, et al. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Curr Oncol. 2014;21:e129–36.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  70. Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23:4888–96.

    Article  CAS  PubMed  Google Scholar 

  71. Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15:219–26.

    Article  PubMed  Google Scholar 

  72. Ammori JB, Kemeny NE, Fong Y, et al. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. Ann Surg Oncol. 2013;20:2901–7. Single-institution series of patients with initially unresectable CLM following administration of HAI plus systemic chemotherapy were converted to resectable disease.

    Article  PubMed  Google Scholar 

  73. Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27:3465–71.

    Article  PubMed Central  PubMed  Google Scholar 

  74. D’Angelica MI, Correa-Gallego C, Paty PB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261:353–60.

    Article  PubMed  Google Scholar 

  75. Hughes KS, Rosenstein RB, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum. 1988;31:1–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  76. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986;100:278–84.

    CAS  PubMed  Google Scholar 

  77. Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol. 2010;28:2300–9.

    Article  CAS  PubMed  Google Scholar 

  78. Nelson R, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver. Cochrane Database Syst Rev. 2006:CD003770.

  79. Bozzetti F, Doci R, Bignami P, Morabito A, Gennari L. Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach. Ann Surg. 1987;205:264–70.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–48.

    Article  CAS  PubMed  Google Scholar 

  81. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol. 2002;20:1499–505.

    Article  PubMed  Google Scholar 

  82. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg. 1998;228:756–62.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  83. Goere D, Benhaim L, Bonnet S, et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg. 2013;257:114–20.

    Article  PubMed  Google Scholar 

  84. Feng WM, Tang CW, Huang SX, et al. Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from stage III colorectal cancer after curative resection. Hepatogastroenterology. 2012;59:1087–90.

    CAS  PubMed  Google Scholar 

  85. Kemeny NE, Jarnagin WR, Capanu M, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol. 2011;29:884–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  86. House MG, Kemeny NE, Gonen M, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg. 2011;254:851–6.

    Article  PubMed  Google Scholar 

  87. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med. 2005;352:734–5.

    Article  CAS  PubMed  Google Scholar 

  88. Bolton JS, O’Connell MJ, Mahoney MR, et al. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Clin Colorectal Cancer. 2012;11:31–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  89. Alberts SR, Roh MS, Mahoney MR, et al. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin Oncol. 2010;28:853–8.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Madhu Subramanian, Michael A. Choti, and Adam C. Yopp declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA

    Madhu Subramanian, Michael A. Choti & Adam C. Yopp

Authors
  1. Madhu Subramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael A. Choti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adam C. Yopp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam C. Yopp.

Additional information

This article is part of the Topical Collection on Colorectal Cancer Hepatic Metastases

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Subramanian, M., Choti, M.A. & Yopp, A.C. Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases: Making a Comeback?. Curr Colorectal Cancer Rep 11, 231–240 (2015). https://doi.org/10.1007/s11888-015-0277-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-015-0277-2

Keywords

Search

Navigation